Chemodex

Entecavir monohydrate

CHF 95.00
In stock
CDX-E0229-M05050 mgCHF 95.00
CDX-E0229-M200200 mgCHF 285.00
More Information
Product Details
Synonyms Baraclude; BMS 200475; SQ 34,676; 2-Amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one monohydrate
Product Type Chemical
Properties
Formula C12H15N5O3 . H2O
MW 295.29
CAS 209216-23-9
Source/Host Chemicals Synthetic
Purity Chemicals ≥98% (HPLC)
Appearance White to off-white powder.
Solubility Solube in DMSO (10mg/ml), DMF (10mg/ml) or methanol. Sparingly soluble in water.
Identity Determined by 1H-NMR.
Declaration Manufactured by Chemodex.
Other Product Data

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.

InChi Key YXPVEXCTPGULBZ-WQYNNSOESA-N
Smiles O=C1C2=C(N([C@H]3C[C@H](O)[C@@H](CO)C3=C)C=N2)NC(N)=N1.O
Shipping and Handling
Shipping AMBIENT
Short Term Storage +20°C
Long Term Storage +20°C
Handling Advice Protect from light and moisture.
Use/Stability Stable for at least 2 years after receipt when stored at RT.
Documents
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF
Description

Entecavir is an oral antiviral drug used in the treatment of hepatitis B (HBV) infection. It is marketed under the trade name Baraclude (BMS). Entecavir is a potent deoxyguanosine nucleoside analog with antiviral activity selective for hepadnaviruses. In vitro, the active intracellular form of entecavir, entecavir triphosphate, demonstrates a higher binding affinity for HBV DNA polymerase than the natural guanosine triphosphate substrate and effectively inhibits HBV DNA replication at 3 stages in the replication pathway: priming, reverse transcription and DNA-dependent DNA synthesis. Can be also used as a reference compound.

Product References

(1) S.F. Innaimo, et al.; Antimicrob. Agents Chemother. 41, 1444 (1997) | (2) M. Seifer, et al.; Antimicrob. Agents Chemother. 42, 3200 (1998) | (3) P. Honkoop & R.A. De Man; Expert. Opin. Investig. Drugs 12, 683 (2003) (Review) | (4) S.J. Matthews; Clin. Ther. 28, 184 (2006) (Review) | (5) K.A. Sims & A.M. Woodland; Pharmacotherapy 26, 1745 (2006) (Review) | (6) P.N. Cheng & T.T. Chang; Expert Rev. Anti. Infect. Ther. 6, 569 (2008) (Review)

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.